These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15713410)

  • 41. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
    Yamazaki S; Nguyen L; Vekich S; Shen Z; Yin MJ; Mehta PP; Kung PP; Vicini P
    J Pharmacol Exp Ther; 2011 Sep; 338(3):964-73. PubMed ID: 21680888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radester, a novel inhibitor of the Hsp90 protein folding machinery.
    Shen G; Blagg BS
    Org Lett; 2005 May; 7(11):2157-60. PubMed ID: 15901158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.
    Lee-Dutra A; Wiener DK; Arienti KL; Liu J; Mani N; Ameriks MK; Axe FU; Gebauer D; Desai PJ; Nguyen S; Randal M; Thurmond RL; Sun S; Karlsson L; Edwards JP; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2370-4. PubMed ID: 20153648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based discovery of a new class of Hsp90 inhibitors.
    Barril X; Brough P; Drysdale M; Hubbard RE; Massey A; Surgenor A; Wright L
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5187-91. PubMed ID: 16202589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis, crystal structure and biological evaluation of novel 2-(5-(hydroxymethyl)-3-phenyl-1H-pyrazol-1-yl)-1-phenylethanol derivatives.
    Zheng LW; Zhu J; Zhao BX; Huang YH; Ding J; Miao JY
    Eur J Med Chem; 2010 Dec; 45(12):5792-9. PubMed ID: 20947221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
    J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors.
    Yang Y; Liu H; Du J; Qin J; Yao X
    J Mol Model; 2011 Dec; 17(12):3241-50. PubMed ID: 21369933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Solution-phase parallel synthesis of Hsp90 inhibitors.
    Cho-Schultz S; Patten MJ; Huang B; Elleraas J; Gajiwala KS; Hickey MJ; Wang J; Mehta PP; Kang P; Gehring MR; Kung PP; Sutton SC
    J Comb Chem; 2009; 11(5):860-74. PubMed ID: 19583220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
    Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
    J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.
    Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH
    J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
    Al-Sha'er MA; Taha MO
    J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
    Kung PP; Huang B; Zhang G; Zhou JZ; Wang J; Digits JA; Skaptason J; Yamazaki S; Neul D; Zientek M; Elleraas J; Mehta P; Yin MJ; Hickey MJ; Gajiwala KS; Rodgers C; Davies JF; Gehring MR
    J Med Chem; 2010 Jan; 53(1):499-503. PubMed ID: 19908836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
    Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of inhibitory activities of Hsp90 inhibitors.
    Swuec P; Barlow DJ
    Bioorg Med Chem; 2012 Jan; 20(1):408-14. PubMed ID: 22112537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A fluorescence polarization assay for inhibitors of Hsp90.
    Howes R; Barril X; Dymock BW; Grant K; Northfield CJ; Robertson AG; Surgenor A; Wayne J; Wright L; James K; Matthews T; Cheung KM; McDonald E; Workman P; Drysdale MJ
    Anal Biochem; 2006 Mar; 350(2):202-13. PubMed ID: 16460658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors.
    Karthikeyan G; Zambaldo C; Barluenga S; Zoete V; Karplus M; Winssinger N
    Chemistry; 2012 Jul; 18(29):8978-86. PubMed ID: 22696415
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.
    Ernst JT; Liu M; Zuccola H; Neubert T; Beaumont K; Turnbull A; Kallel A; Vought B; Stamos D
    Bioorg Med Chem Lett; 2014 Jan; 24(1):204-8. PubMed ID: 24332488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.
    Dymock B; Barril X; Beswick M; Collier A; Davies N; Drysdale M; Fink A; Fromont C; Hubbard RE; Massey A; Surgenor A; Wright L
    Bioorg Med Chem Lett; 2004 Jan; 14(2):325-8. PubMed ID: 14698151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity.
    Marcyk PT; LeBlanc EV; Kuntz DA; Xue A; Ortiz F; Trilles R; Bengtson S; Kenney TMG; Huang DS; Robbins N; Williams NS; Krysan DJ; Privé GG; Whitesell L; Cowen LE; Brown LE
    J Med Chem; 2021 Jan; 64(2):1139-1169. PubMed ID: 33444025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ligand-Induced Conformational Changes in HSP90 Monitored Time Resolved and Label Free-Towards a Conformational Activity Screening for Drug Discovery.
    Güldenhaupt J; Amaral M; Kötting C; Schartner J; Musil D; Frech M; Gerwert K
    Angew Chem Int Ed Engl; 2018 Jul; 57(31):9955-9960. PubMed ID: 29772085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.